Sandra Calvin Sells 925 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sandra Calvin sold 925 shares of the business’s stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $18.94, for a total transaction of $17,519.50. Following the completion of the transaction, the chief accounting officer now owns 54,002 shares in the company, valued at $1,022,797.88. The trade was a 1.68 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Sandra Calvin also recently made the following trade(s):

• On Thursday, December 26th, Sandra Calvin sold 15,000 shares of Travere Therapeutics stock. The stock was sold at an average price of $17.22, for a total value of $258,300.00.
• On Monday, November 25th, Sandra Calvin sold 12,090 shares of Travere Therapeutics stock. The stock was sold at an average price of $18.30, for a total value of $221,247.00.

Travere Therapeutics Stock Up 6.9 %

Shares of NASDAQ TVTX traded up $1.35 during trading on Thursday, reaching $20.81. The company had a trading volume of 2,031,403 shares, compared to its average volume of 1,331,242. Travere Therapeutics, Inc. has a 12-month low of $5.12 and a 12-month high of $20.89. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96. The business’s 50-day moving average is $18.28 and its 200 day moving average is $14.79. The stock has a market cap of $1.62 billion, a PE ratio of -4.57 and a beta of 0.70.

Travere Therapeutics (NASDAQ:TVTX) last issued its earnings results on Thursday, October 31st. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.01. Travere Therapeutics had a negative net margin of 172.75% and a negative return on equity of 537.74%. The business had revenue of $62.90 million during the quarter, compared to analysts’ expectations of $60.87 million. During the same period in the previous year, the company earned ($1.17) earnings per share. The business’s revenue for the quarter was up 69.6% compared to the same quarter last year. As a group, equities analysts forecast that Travere Therapeutics, Inc. will post -3.92 earnings per share for the current fiscal year.

Institutional Trading of Travere Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC raised its stake in shares of Travere Therapeutics by 33.9% in the second quarter. Millennium Management LLC now owns 2,949,335 shares of the company’s stock worth $24,244,000 after purchasing an additional 747,406 shares during the last quarter. Emerald Advisers LLC raised its position in Travere Therapeutics by 19.8% in the 3rd quarter. Emerald Advisers LLC now owns 1,960,659 shares of the company’s stock worth $27,430,000 after buying an additional 323,513 shares during the last quarter. Finepoint Capital LP boosted its holdings in shares of Travere Therapeutics by 0.3% during the 3rd quarter. Finepoint Capital LP now owns 1,782,267 shares of the company’s stock valued at $24,934,000 after acquiring an additional 5,539 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Travere Therapeutics by 3.9% during the third quarter. Geode Capital Management LLC now owns 1,731,045 shares of the company’s stock valued at $24,222,000 after purchasing an additional 64,744 shares during the last quarter. Finally, Emerald Mutual Fund Advisers Trust lifted its position in Travere Therapeutics by 26.0% during the third quarter. Emerald Mutual Fund Advisers Trust now owns 1,185,709 shares of the company’s stock valued at $16,588,000 after purchasing an additional 244,444 shares during the period.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Wedbush upped their target price on Travere Therapeutics from $17.00 to $25.00 and gave the company an “outperform” rating in a report on Wednesday, October 9th. Piper Sandler upped their price objective on shares of Travere Therapeutics from $12.00 to $22.00 and gave the stock a “neutral” rating in a report on Thursday, November 14th. Barclays lifted their target price on shares of Travere Therapeutics from $18.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, November 1st. Guggenheim increased their price target on shares of Travere Therapeutics from $23.00 to $41.00 and gave the stock a “buy” rating in a research note on Wednesday, October 9th. Finally, Citigroup cut their price objective on Travere Therapeutics from $23.00 to $19.00 and set a “buy” rating on the stock in a research report on Friday, September 27th. One investment analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $24.00.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.